MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Amgen Inc

Deschisă

SectorSănătate

280.27 0.02

Rezumat

Modificarea prețului

24h

Curent

Minim

276.26

Maxim

280.53

Indicatori cheie

By Trading Economics

Venit

-2.2B

627M

Vânzări

586M

9.1B

P/E

Medie Sector

36.153

57.333

EPS

5.31

Randament dividend

3.43

Marjă de profit

6.901

Angajați

28,000

EBITDA

-517M

2.9B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+16.62% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.43%

2.63%

Următoarele câștiguri

1 mai 2025

Data viitoare de dividende

6 iun. 2025

Următoarea dată ex-dividende

16 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-6B

147B

Deschiderea anterioară

280.25

Închiderea anterioară

280.27

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Amgen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 feb. 2025, 21:29 UTC

Câștiguri

Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains

30 oct. 2024, 20:18 UTC

Câștiguri

Amgen Posts Higher 3Q Sales on Strong Demand

10 apr. 2025, 05:00 UTC

Câștiguri

Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the Next Winner. -- Barrons.com

28 feb. 2025, 12:00 UTC

Top știri

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 feb. 2025, 21:02 UTC

Câștiguri

Amgen 4Q SAles Included $1.2 B of Sales From Rare Disease Products >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen 4Q Worldwide Neulasta Sales $98M >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen 4Q Worldwide Enbrel Sales $1.01B >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen 4Q Worldwide Prolia Sales $1.17B >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen Sees FY Rev $34.3B-$35.7B >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen 4Q Adj EPS $5.31 >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen 4Q Worldwide XGEVA Sales $561M >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen Sees FY EPS $10.89-EPS $12.14 >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen 4Q Rev $9.1B >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen 4Q EPS $1.16 >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen 4Q Net $627M >AMGN

28 ian. 2025, 10:30 UTC

Top știri

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

27 dec. 2024, 07:00 UTC

Câștiguri

3 Healthcare Stocks to Buy for a 2025 Rebound -- Barrons.com

23 dec. 2024, 15:04 UTC

Top știri

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13 dec. 2024, 14:53 UTC

Top știri

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

30 nov. 2024, 12:00 UTC

Top știri

Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ

26 nov. 2024, 12:34 UTC

Top știri

Amgen Drug Cut Weight in Closely Watched Study -- WSJ

4 nov. 2024, 12:00 UTC

Top știri

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

30 oct. 2024, 20:02 UTC

Câștiguri

Amgen 3Q Sales From Rare Disease Products $1.2B >AMGN

30 oct. 2024, 20:02 UTC

Câștiguri

Amgen CEO: Strong Growth in Sales, Earnings in 3Q Reflects Momentum Being Built Throughout Business>AMGN

30 oct. 2024, 20:02 UTC

Câștiguri

Amgen: 2024 Buybacks Not to Exceed $500M>AMGN

30 oct. 2024, 20:02 UTC

Câștiguri

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30 oct. 2024, 20:02 UTC

Câștiguri

Amgen 3Q Worldwide Prolia Sales $1.05B >AMGN

30 oct. 2024, 20:01 UTC

Câștiguri

Amgen 3Q Worldwide Enbrel Sales $825M >AMGN

30 oct. 2024, 20:01 UTC

Câștiguri

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

Comparație

Modificare preț

Amgen Inc Așteptări

Obiectiv de preț

By TipRanks

16.62% sus

Prognoză pe 12 luni

Medie 326.36 USD  16.62%

Maxim 389 USD

Minim 280 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAmgen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

18 ratings

9

Cumpărare

8

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

278.68 / 295.18Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.